Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01879670
Other study ID # 2012HSB002B
Secondary ID FS/13/34/30173
Status Terminated
Phase N/A
First received June 11, 2013
Last updated October 27, 2015
Start date June 2013
Est. completion date June 2014

Study information

Verified date October 2015
Source Royal Brompton & Harefield NHS Foundation Trust
Contact n/a
Is FDA regulated No
Health authority United Kingdom: Research Ethics CommitteeUnited Kingdom: National Institute for Health Research
Study type Observational

Clinical Trial Summary

Heart failure is a common condition, and the number of people with advanced disease continues to increase. We need new treatments that improve patients' symptoms and extend life. Recently the new CircuLite Synergy pump has come into use. It is the smallest pump manufactured to date and does not cover the full work of the heart, instead providing "partial" support. One interesting thing about this is that taking some strain off the heart might allow the muscle to repair and rebuild its own strength. This process is called reverse remodelling, and is the topic of this research. Our hypothesis is that "partial" support improves patients' symptoms and causes improvement in heart muscle function. We also want to examine the best techniques for assessing this, including new scanning and molecular tests, and study some practical aspects of the pump to do with blood clotting.


Description:

The CircuLite Synergy pump is a new minimally-invasive partial support left ventricular assist device (LVAD) that pumps blood from the left atrium to the right subclavian artery. Ex vivo pilot data suggests that the Synergy pump induces structural reverse remodelling, which proposes the Synergy device as a new disease-modifying therapy. We will assess whether the Synergy pump facilitates functional, structural and molecular LV reverse remodelling in vivo; assess how this can be determined and predicted by analysis of circulating micro RNA profiles and specific echocardiographic parameters; and evaluate the haematological abnormalities associated with this new LVAD.

We will address these questions with a prospective, observational study comparing patients implanted with the Synergy device with matched heart failure controls. The two study centres will be Royal Brompton & Harefield NHS Foundation Trust (Harefield Hospital) and University Hospitals Leuven, Belgium. We will recruit a total of 64 patients. The primary outcome will be change in peak VO2 at 6 months. Secondary outcomes will include functional parameters, profiling of circulating microRNA, multimodal echocardiographic assessment and comprehensive assessment of platelet activation and coagulopathy.

We will quantify the LV reverse remodelling associated with partial support; define new echo and microRNA markers of reverse remodelling for clinical use, with insights into underlying pathophysiology; and describe the haematological profile of these patients to guide future antiplatelet and anticoagulant therapy.


Recruitment information / eligibility

Status Terminated
Enrollment 2
Est. completion date June 2014
Est. primary completion date June 2014
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

- Patients with ischaemic or dilated cardiomyopathy aged 18 to 80 years.

- Symptoms categorised by INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support) at level 3-6 despite optimal tolerated medical therapy. Practically this includes patients who are in hospital or managing at home with substantial dependence on hospital care.

- Peak VO2 <15ml/kg/min with respiratory exchange ratio>1 on cardiopulmonary exercise testing OR a 6-minute walking distance <300m OR inability to perform an exercise test due to the severity of heart failure.

- Informed consent obtained prior to entering the study.

Exclusion Criteria:

- Cause of heart failure due to or associated with uncorrected thyroid disease, obstructive cardiomyopathy, pericardial disease, amyloidosis, or active myocarditis

- Body surface area <1.2M2 or >2.3M2, or body mass index >32 kg/M2.

- Severe chronic obstructive pulmonary disease as evidenced by forced expiratory volume in 1 second <50% of predicted.

- History of pulmonary hypertension with maintained pulmonary vascular resistance measured > 4 Wood units or transpulmonary gradient >14mmHg.

- Pregnancy.

- Evidence of intrinsic hepatic disease defined as liver enzyme levels > 5 times the upper limit of normal within 4 days before enrolment, severe liver dysfunction, cirrhosis or portal hypertension.

- Occurrence of stroke within 90 days before enrolment.

- Impairment of cognitive function or presence of any form of irreversible dementia.

- Recent history of psychiatric disease (including severe drug or alcohol abuse) that is likely to impair compliance with the study protocol.

- Platelet count <50 x103mm3 within 24 hours before enrolment.

- Creatinine clearance < 30ml/min.

- High probability of non-compliance.

- The patient is deemed unsuitable by the clinical team for other reasons.

Study Design

Observational Model: Case Control, Time Perspective: Prospective


Related Conditions & MeSH terms


Intervention

Device:
CircuLite Synergy left ventricular assist device


Locations

Country Name City State
Belgium Universitaire Ziekenhuizen Leuven Leuven
United Kingdom Royal Brompton & Harefield NHS Foundation Trust London

Sponsors (2)

Lead Sponsor Collaborator
Royal Brompton & Harefield NHS Foundation Trust Universitaire Ziekenhuizen Leuven

Countries where clinical trial is conducted

Belgium,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in maximal aerobic exercise capacity (peak VO2) 6 months No
Secondary Change in 6-minute walk distance 6 months No
Secondary Change in New York Heart Association (NYHA) functional class 6 months No
Secondary Change in B-type natriuretic peptide 6 months No
Secondary Change in ventricular dimensions as measured by echocardiography 6 months No
Secondary Change in ventricular strain as measured by echocardiography 6 months No
Secondary Change in circulating microRNA expression profile 6 months No
Secondary Change in ventilatory equivalent for carbon dioxide (VE/VCO2) slope 6 months No
Secondary Change in haemodynamic parameters at right heart catheterisation 6 months No
Secondary Change in quality of life score 6 months No
Secondary Accumulated days of hospital inpatient stay due to cardiovascular reasons 6 months No
Secondary Incidence of significant haematological derangements 6 months No
Secondary Number of participants suffering adverse events 'Adverse events' are defined as major bleeding, thromboembolism, stroke, infection, perioperative complications, right ventricular failure, device-related morbidity and device failure. 6 months Yes
See also
  Status Clinical Trial Phase
Recruiting NCT05654272 - Development of CIRC Technologies
Recruiting NCT05196659 - Collaborative Quality Improvement (C-QIP) Study N/A
Recruiting NCT05650307 - CV Imaging of Metabolic Interventions
Active, not recruiting NCT05896904 - Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction N/A
Completed NCT05077293 - Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure
Recruiting NCT05631275 - The Role of Bioimpedance Analysis in Patients With Chronic Heart Failure and Systolic Ventricular Dysfunction
Enrolling by invitation NCT05564572 - Randomized Implementation of Routine Patient-Reported Health Status Assessment Among Heart Failure Patients in Stanford Cardiology N/A
Enrolling by invitation NCT05009706 - Self-care in Older Frail Persons With Heart Failure Intervention N/A
Recruiting NCT04177199 - What is the Workload Burden Associated With Using the Triage HF+ Care Pathway?
Terminated NCT03615469 - Building Strength Through Rehabilitation for Heart Failure Patients (BISTRO-STUDY) N/A
Recruiting NCT06340048 - Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure Phase 1/Phase 2
Recruiting NCT05679713 - Next-generation, Integrative, and Personalized Risk Assessment to Prevent Recurrent Heart Failure Events: the ORACLE Study
Completed NCT04254328 - The Effectiveness of Nintendo Wii Fit and Inspiratory Muscle Training in Older Patients With Heart Failure N/A
Completed NCT03549169 - Decision Making for the Management the Symptoms in Adults of Heart Failure N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Enrolling by invitation NCT05538611 - Effect Evaluation of Chain Quality Control Management on Patients With Heart Failure
Recruiting NCT04262830 - Cancer Therapy Effects on the Heart
Completed NCT06026683 - Conduction System Stimulation to Avoid Left Ventricle Dysfunction N/A
Withdrawn NCT03091998 - Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support Phase 1
Recruiting NCT05564689 - Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy